|
Andrew Arnold, M.D.Murray-Heilig Chair in Molecular MedicineProfessor of Medicine and Genetics and Genome Sciences Chief, Division of Endocrinology and Metabolism Director, Center for Molecular Oncology and Chief Academic Officer, Carole and Ray Neag Comprehensive Cancer Center Director, Office of Physician-Scientist Career Development
|
|||||||||||
Pathogenesis of parathyroid and other endocrine tumors, and role of the cyclin D1 oncogene in neoplasia
| No data available |
Post-Graduate Training
| Training | Institution | Specialty |
|---|---|---|
| Residency | University of Chicago | Internal Medicine |
| Fellowship | Massachusetts General Hospital | Medicine, Endocrinology |
| Fellowship | National Cancer Institute/NIH | Molecular Oncology |
Awards
| Name of Award/Honor | Awarding Organization |
|---|---|
| Refer to Abbreviated CV Link |
Parathyroid disorders; genetic/inherited endocrine tumor syndromes
The most longstanding interest of our laboratory has been in the molecular genetic underpinnings of tumors of the endocrine glands. It was in the context of a search for a parathyroid tumor oncogene lying adjacent to a clonal chromosomal breakpoint that we discovered cyclin D1 (PRAD1). Cyclin D1 has proven to play a key role in cell cycle regulation, and has emerged as a major human oncogene, important in multiple types of tumors including breast cancer and B-cell lymphoma. We are currently pursuing a number of approaches, including the use of transgenic mouse models, to learn more about the precise mechanisms by which cyclin D1 exerts its oncogenic effects. In addition to the cyclin D1 work, we are continuing a major initiative seeking additional genes that contribute to endocrine neoplasia. In this context, we identified the HRPT2 (CDC73) gene as a major factor in the development of malignant parathyroid tumors, a finding that carries important clinical implications.
Accepting Lab Rotation Students: Fall 2022 and Spring 2023
Journal Articles
-
Epidemiology, Pathophysiology, and Genetics of Primary Hyperparathyroidism.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2022 Nov;37(11):2315-2329
-
Parathyroid Hormone Regulates Circulating Levels of Sclerostin and FGF23 in a Primary Hyperparathyroidism Model
Journal of the Endocrine Society, 2022, Vol.6 (4), p.bvac027-bvac027 2022 Feb;
-
GCM2 Variants in Familial and Multiglandular Primary Hyperparathyroidism
The journal of clinical endocrinology and metabolism, 2022, Vol.107 (5), p.e2021-e2026 2022 Jan;
-
Parafibromin Abnormalities in Ossifying Fibroma.
Journal of the Endocrine Society 2021 Jul;5(7):bvab087
-
Molecular analysis of cyclin D1 modulators PRKN and FBX4 as candidate tumor suppressors in sporadic parathyroid adenomas.
Endocrine connections 2021 Mar;10(3):302-308
Book Chapters
-
Gene test interpretation: MEN1 (multiple endocrine neoplasia)
In: Post TW, ed. UpToDate. Waltham, MA: UpToDate, Inc., 2022. 2022 Nov;
-
Multiple endocrine neoplasia type 1: Genetics
In: Post TW, ed. UpToDate. Waltham, MA: UpToDate, Inc., 2022. 2022 Sep;
-
Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis
In: Post TW, ed. UpToDate. Waltham, MA: UpToDate, Inc., 2022. 2022 Sep;
-
Multiple endocrine neoplasia type 1: Management
In: Post TW, ed. UpToDate. Waltham, MA: UpToDate, Inc., 2022. 2022 Sep;
-
Primary hyperparathyroidism: pathogenesis and etiology
In: Post TW, ed. UpToDate. Waltham, MA: UpToDate, Inc., 2022. 2022 Apr;
-
Parathyroid carcinoma
In: Post TW, ed. UpToDate. Waltham, MA: UpToDate, Inc., 2022. 2022 Jan;
Abstracts
-
Hormonal regulation of biomineralization.
Nature reviews. Endocrinology 2021 May;17(5):261-275